Posted by Michael Wonder on 21 Aug 2023
Patients get antsy amid protracted price bargaining for Spinraza, Evrysdi
21 August 2023 - Drug price negotiations for two spinal muscular atrophy drugs --Spinraza (nusinersen sodium) and Evrysdi (risdiplam) – have reportedly failed to settle by the deadline, deepening the concerns of Korean patients, according to sources Monday.
The National Health Insurance Service failed to narrow differences in setting drug prices for Spinraza and Evrysdi by Friday of last week, the deadline for negotiations with the companies, the sources said.
